Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance

Cheng,Jiwen; Chen,Yanke; Zhao,Pu; Li,Na; Lu,Jianwen; Li,Jianhui; Liu,Zhengwen; Lv,Yi; Huang,Chen

doi:10.3892/ol.2017.5882

Dysregulation of miR-638 in hepatocellular carcinoma and its clinical significance

Authors:
- Jiwen Cheng
- Yanke Chen
- Pu Zhao
- Na Li
- Jianwen Lu
- Jianhui Li
- Zhengwen Liu
- Yi Lv
- Chen Huang
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Institute of Advanced Surgical Technology and Engineering, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Genetics and Cell Biology, Environment and Genes Related to Diseases Key Laboratory of Education Ministry, College of Medicine, Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Neonatology, The Third Affiliated Hospital of the School of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi 710068, P.R. China, Department of Infectious Diseases, The First Affiliated Hospital of The School of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi 710061, P.R. China, Department of Surgical Oncology, The Third Affiliated Hospital of The School of Medicine of Xi'an Jiaotong University, Xi'an, Shaanxi 710068, P.R. China
Published online on: March 21, 2017 https://doi.org/10.3892/ol.2017.5882
Pages: 3859-3865

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

MicroRNAs (miRNAs/miRs) have been identified as important post-transcriptional regulators in healthy liver physiology and liver diseases. However, the clinical significance of miR-638 in hepatocellular carcinoma (HCC) remains unclear. The aim of the present study was to investigate the status of miR‑638 expression in HCC and to determine its clinical significance. The expression of miR‑638 was evaluated in 60 HCC tissues samples and HCC SMMC‑7721, HepG2 and Hep3B cell lines using reverse transcription‑quantitative polymerase chain reaction. The association between the expression of miR-638 and the clinicopathological characteristics of patients with HCC was analyzed. The proportion of HCC patients with low miR‑638 expression was identified as 68.3% (41/60). Furthermore, significantly lower miR‑638 expression was identified in HCC tissue samples compared with the healthy control group (P=0.031). miR‑638 expression was significantly lower in SMMC‑7721 (P=0.021), HepG2 (P=0.005) and Hep3B (P=0.003) cells compared with the healthy human hepatic HL‑7702 cell line. In addition, miR‑638 expression was correlated with α‑fetoprotein levels (P=0.042) and portal vein invasion (P=0.025). The area under curve was identified as 0.71 (95% confidence interval=0.63‑0.79; P=0.001). The cut‑off value for miR‑638 was the median 2-Δ∆Cq=0.125. In conclusion, miR‑638 may be involved in the progression of HCC and act as a potential biomarker for the prediction of HCC.

View Figures

View References

1	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
2	Berindan-Neagoe I, Pdel Monroig C, Pasculli B and Calin GA: MicroRNAome genome: A treasure for cancer diagnosis and therapy. CA Cancer J Clin. 64:311–336. 2014. View Article : Google Scholar : PubMed/NCBI
3	Sen R, Ghosal S, Das S, Balti S and Chakrabarti J: Competing endogenous RNA: The key to posttranscriptional regulation. ScientificWorldJournal. 2014:8962062014. View Article : Google Scholar : PubMed/NCBI
4	Mendell JT and Olson EN: MicroRNAs in stress signaling and human disease. Cell. 148:1172–1187. 2012. View Article : Google Scholar : PubMed/NCBI
5	Calin GA and Croce CM: MicroRNA signatures in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
6	Esquela-Kerscher A and Slack FJ: Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer. 6:259–269. 2006. View Article : Google Scholar : PubMed/NCBI
7	Zhao LY, Yao Y, Han J, Yang J, Wang XF, Tong DD, Song TS, Huang C and Shao Y: miR-638 suppresses cell proliferation in gastric cancer by targeting Sp2. Dig Dis Sci. 59:1743–1753. 2014. View Article : Google Scholar : PubMed/NCBI
8	Tan X, Peng J, Fu Y, An S, Rezaei K, Tabbara S, Teal CB, Man YG, Brem RF and Fu SW: miR-638 mediated regulation of BRCA1 affects DNA repair and sensitivity to UV and cisplatin in triple-negative breast cancer. Breast Cancer Res. 16:4352014. View Article : Google Scholar : PubMed/NCBI
9	Sand M, Skrygan M, Sand D, Georgas D, Hahn SA, Gambichler T, Altmeyer P and Bechara FG: Expression of microRNAs in basal cell carcinoma. Br J Dermatol. 167:847–855. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhu DX, Zhu W, Fang C, Fan L, Zou ZJ, Wang YH, Liu P, Hong M, Miao KR, Liu P, et al: miR-181a/b significantly enhances drug sensitivity in chronic lymphocytic leukemia cells via targeting multiple anti-apoptosis genes. Carcinogenesis. 33:1294–1301. 2012. View Article : Google Scholar : PubMed/NCBI
11	Lin Y, Zeng Y, Zhang F, Xue L, Huang Z, Li W and Guo M: Characterization of microRNA expression profiles and the discovery of novel microRNAs involved in cancer during human embryonic development. PLoS One. 8:e692302013. View Article : Google Scholar : PubMed/NCBI
12	Tao ZH, Wan JL, Zeng LY, Xie L, Sun HC, Qin LX, Wang L, Zhou J, Ren ZG, Li YX, et al: miR-612 suppresses the invasive-metastatic cascade in hepatocellular carcinoma. J Exp Med. 210:789–803. 2013. View Article : Google Scholar : PubMed/NCBI
13	Zhang J, Fei B, Wang Q, Song M, Yin Y, Zhang B, Ni S, Guo W, Bian Z, Quan C, et al: MicroRNA-638 inhibits cell proliferation, invasion and regulates cell cycle by targeting tetraspanin 1 in human colorectal carcinoma. Oncotarget. 5:12083–12096. 2014. View Article : Google Scholar : PubMed/NCBI
14	Xia Y, Wu Y, Liu B, Wang P and Chen Y: Downregulation of miR-638 promotes invasion and proliferation by regulating SOX2 and induces EMT in NSCLC. FEBS Lett. 588:2238–2245. 2014. View Article : Google Scholar : PubMed/NCBI
15	Liu X, Wang T, Wakita T and Yang W: Systematic identification of microRNA and messenger RNA profiles in hepatitis C virus-infected human hepatoma cells. Virology. 398:57–67. 2010. View Article : Google Scholar : PubMed/NCBI
16	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
17	Tay Y, Zhang J, Thomson AM, Lim B and Rigoutsos I: MicroRNAs to Nanog, Oct4 and Sox2 coding regions modulate embryonic stem cell differentiation. Nature. 455:1124–1128. 2008. View Article : Google Scholar : PubMed/NCBI
18	Lytle JR, Yario TA and Steitz JA: Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′UTR as in the 3′UTR. Proc Natl Acad Sci USA. 104:9667–9672. 2007. View Article : Google Scholar : PubMed/NCBI
19	Peiró-Chova L, Peña-Chilet M, López-Guerrero JA, García-Giménez JL, Alonso-Yuste E, Burgues O, Lluch A, Ferrer-Lozano J and Ribas G: High stability of microRNAs in tissue samples of compromised quality. Virchows Arch. 463:765–774. 2013. View Article : Google Scholar : PubMed/NCBI
20	Zhang X, Chen J, Radcliffe T, Lebrun DP, Tron VA and Feilotter H: An array-based analysis of microRNA expression comparing matched frozen and formalin-fixed paraffin-embedded human tissue samples. J Mol Diagn. 10:513–519. 2008. View Article : Google Scholar : PubMed/NCBI
21	Siebolts U, Varnholt H, Drebber U, Dienes HP, Wickenhauser C and Odenthal M: Tissues from routine pathology archives are suitable for microRNA analyses by quantitative PCR. J Clin Pathol. 62:84–88. 2009. View Article : Google Scholar : PubMed/NCBI
22	Liu CG, Calin GA, Volinia S and Croce CM: MicroRNA expression profiling using microarrays. Nat Protoc. 3:563–578. 2008. View Article : Google Scholar : PubMed/NCBI
23	Benes V and Castoldi M: Expression profiling of microRNA using real-time quantitative PCR, how to use it and what is available. Methods. 50:244–249. 2010. View Article : Google Scholar : PubMed/NCBI
24	Jin W, Grant J, Stothard P, Moore SS and Guan LL: Characterization of bovine miRNAs by sequencing and bioinformatics analysis. BMC Mol Biol. 10:902009. View Article : Google Scholar : PubMed/NCBI
25	Sempere LF and Korc M: A method for conducting highly sensitive microRNA in situ hybridization and immunohistochemical analysis in pancreatic cancer. Methods Mol Biol. 980:43–59. 2013. View Article : Google Scholar : PubMed/NCBI
26	Griffiths-Jones S, Saini HK, Van Dongen S and Enright AJ: Mirbase: Tools for microRNA genomics. Nucleic Acids Res. 36:D154–D158. 2008. View Article : Google Scholar : PubMed/NCBI
27	Parasramka MA, Ali S, Banerjee S, Deryavoush T, Sarkar FH and Gupta S: Garcinol sensitizes human pancreatic adenocarcinoma cells to gemcitabine in association with microRNA signatures. Mol Nutr Food Res. 57:235–248. 2013. View Article : Google Scholar : PubMed/NCBI
28	Liu N, Cui RX, Sun Y, Guo R, Mao YP, Tang LL, Jiang W, Liu X, Cheng YK, He QM, et al: A four-miRNA signature identified from genome-wide serum miRNA profiling predicts survival in patients with nasopharyngeal carcinoma. Int J Cancer. 134:1359–1368. 2014. View Article : Google Scholar : PubMed/NCBI
29	Jiang X, Tan J, Li J, Kivimäe S, Yang X, Zhuang L, Lee PL, Chan MT, Stanton LW, Liu ET, et al: DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell. 13:529–541. 2008. View Article : Google Scholar : PubMed/NCBI
30	Murphy NC, Biankin AV, Millar EK, McNeil CM, O'Toole SA, Segara D, Crea P, Olayioye MA, Lee CS, Fox SB, et al: Loss of STARD10 expression identifies a group of poor prognosis breast cancers independent of HER2/Neu and triple negative status. Int J Cancer. 126:1445–1453. 2010.PubMed/NCBI
31	Lan J, Guo P, Lin Y, Mao Q, Guo L, Ge J, Li X, Jiang J, Lin X and Qiu Y: Role of glycosyltransferase PomGnT1 in glioblastoma progression. Neuro Oncol. 17:211–222. 2015. View Article : Google Scholar : PubMed/NCBI
32	Kim TO, Park J, Kang MJ, Lee SH, Jee SR, Ryu DY, Yang K and Yi JM: DNA hypermethylation of a selective gene panel as a risk marker for colon cancer in patients with ulcerative colitis. Int J Mol Med. 31:1255–1261. 2013.PubMed/NCBI
33	Hahn S and Hermeking H: ZNF281/ZBP-99: A new player in epithelial-mesenchymal transition, stemness, and cancer. J Mol Med (Berl). 92:571–581. 2014. View Article : Google Scholar : PubMed/NCBI
34	Fernández M, Semela D, Bruix J, Colle I, Pinzani M and Bosch J: Angiogenesis in liver disease. J Hepatol. 50:604–620. 2009. View Article : Google Scholar : PubMed/NCBI
35	Sampat KR and O'Neil B: Antiangiogenic therapies for advanced hepatocellular carcinoma. Oncologist. 18:430–438. 2013. View Article : Google Scholar : PubMed/NCBI